Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Jan;104(1):93-7.
doi: 10.1111/cas.12028. Epub 2012 Nov 8.

Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer

Hidehito Horinouchi  1 , Ikuo Sekine, Minako Sumi, Kazumasa Noda, Koichi Goto, Kiyoshi Mori, Tomohide Tamura
Affiliations
Clinical Trial

Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer

Hidehito Horinouchi et al. Cancer Sci. 2013 Jan.

Abstract

Concurrent chemoradiotherapy is the standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). The long-term feasibility and efficacy of vinorelbine and cisplatin with concurrent thoracic radiotherapy were investigated. Eighteen patients received cisplatin (80 mg/m(2)) on day 1 and vinorelbine (20 mg/m(2) in level 1, and 25 mg/m(2) in level 2) on days 1 and 8 every 4 weeks for four cycles in a phase I trial. Ninety-three patients received the same chemotherapy regimen except for the fixed vinorelbine (20 mg/m(2)) dosage and consolidation therapy with docetaxel (60 mg/m(2), every 3 weeks). The thoracic radiotherapy consisted of a single dose of 2 Gy once daily to a total dose of 60 Gy. A total of 111 patients were analyzed in the present study: male/female, 91/20; median age, 60 years; stage IIIA/IIIB, 50/61; and squamous/non-squamous histology, 26/85. The 3-, 5-, and 7-year overall survival rates (95% CI) were 43.2% (33.9-52.2), 25.2% (17.6-33.5), and 23.2% (15.8-31.4), respectively. The median progression-free survival and median survival time (95% CI) were 13.5 (10.1-16.7) months and 30.0 (24.3-38.8) months, respectively. Four patients (4%) experienced Grade 5 pulmonary toxicities from 4.4 to 9.4 months after the start of treatment. In conclusion, approximately 15% of patients with unresectable stage III NSCLC could be cured with chemoradiotherapy without severe late toxicities after 10 months of follow-up. Although based on the data from highly selected population participated in phase I and phase II trial, this analysis would strengthen and confirm the previous reports concerning concurrent chemoradiotherapy with third generation cytotoxic agents.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progression‐free survival (n = 111). The median progression‐free survival is 13.5 months (95% confidence interval [CI] 10.1–16.7).
Figure 2
Figure 2
Overall survival (n = 111). The median overall survival is 30.0 months (95% confidence interval [CI] 24.3–38.6).
See this image and copyright information in PMC

References

    1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710–7. - PubMed
    1. Meerbeeck V. Staging of non‐small cell lung cancer: consensus, controversies and challenges. Lung Cancer 2001; 34: S95–107. - PubMed
    1. Jett JR, Scott WJ, Rivera MP, Sause WT. Guidelines on treatment of stage IIIB non‐small cell lung cancer. Chest 2003; 123: 221S–5S. - PubMed
    1. Furuse K, Fukuoka M, Kawahara M et al Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non‐small‐cell lung cancer. J Clin Oncol 1999; 17: 2692–9. - PubMed
    1. Fournel P, Robinet G, Thomas P et al Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non‐small‐cell lung cancer: Groupe Lyon‐Saint‐Etienne d'Oncologie Thoracique‐Groupe Francais de Pneumo‐Cancerologie NPC 95‐01 Study. J Clin Oncol 2005; 23: 5910–7. - PubMed

Publication types

MeSH terms